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Surgical Proﬁciency Gain and Survival After Esophagectomy
for Cancer
Sheraz R. Markar, Hugh Mackenzie, Pernilla Lagergren, George B. Hanna, and Jesper Lagergren
A B S T R A C T
Purpose
We aimed to identify the presence and length of esophagectomy proﬁciency gain curves in terms of
short- and long-term mortality for esophageal cancer.
Patients and Methods
Patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 with
follow-up until 2014 were identiﬁed from a well-established, population-based, nationwide Swedish
cohort study. Proﬁciency gain curves were created by using risk-adjusted cumulative sum analysis
for 30-day, 90-day, 1-year, 3-year, and 5-year all-cause and disease-speciﬁc mortality measures.
Similarly, the proﬁciency gain curves for lymph node harvest, resection margin status, and reop-
eration incidence were assessed as performance-contributing factors to the observed changes in
long-term survival.
Results
Esophagectomies in 1,821 patients with esophageal cancer were conducted by 139 surgeons. The
change-point in proﬁciency gain curve for all-cause 30-day mortality was early, at 15 cases, when
mortality decreased from 7.9% to 3.1% (P, .001). Later change-points, which ranged from 35 to 59
cases, were observed for 1-, 3- and 5-year mortality rates, for which all-cause mortality
decreased from 34.9% to 27.7% (P = .011), from 47.4% to 41.5% (P = .049), and from 31.4% to
19.1% (P = .009), respectively. Similar change-points were observed in disease-speciﬁc mortality at
1 and 3 years. There was a continuous increase in lymph node harvest, which did not plateau. Also,
change-points were observed for resection margin with tumor involvement at 17 cases, with a
reduction from20.9% to 15.2% (P= .004), and for reoperation rate at 55 cases, with a reduction from
12.6% to 5.0% (P , .001).
Conclusion
The gain of proﬁciency in esophagectomy for cancer is associated with measurable changes in
short- and long-term mortality results. These ﬁndings indicate a need for structured national training
and mentorship programs for esophageal cancer surgery.
J Clin Oncol 34:1528-1536. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Esophageal cancer is the eighth most common
cancer globally (annually affecting 482,300 peo-
ple), and its incidence is increasing.1-3 The overall
European pooled relative 1-year and 5-year sur-
vival rates are 33.4% (95% CI, 32.9% to 33.9%)
and 9.8% (95% CI, 9.4% to 10.1%), respectively.4
Centralization of esophagectomy to high-volume
centers in recent years has rendered improve-
ments in short-term complications, postoper-
ative mortality,5-7 and long-term survival; surgeon
volume is of greater importance than hospital
volume.8,9
The introduction of minimal-access surgery
has highlighted the effect of surgeons gaining
proﬁciency in new techniques. Typically, studies
that addressed surgeon proﬁciency gain curves in
relation to gastrointestinal cancer have focused
on short-term outcomes.10-12 Few studies have
considered the changes in long-term survival as
surgeons gain proﬁciency in laparoscopic gas-
trectomy,13,14 laparoscopic hemicolectomy,15 and
open esophagectomy.16 These studies often
describe the practice of high-volume surgeons
in high-volume centers and, therefore, do not
reﬂect the average proﬁciency gain curve. A
study on the national proﬁciency gain curve in
the United Kingdom in minimal-access surgery
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has described measurable effects upon short-term clinical
outcomes after esophageal and colorectal cancer resections as
surgeons gain proﬁciency.17 However, to date, no study has been
undertaken to assess the impact of proﬁciency gain on long-
term mortality after cancer resection at a national level. The
objective of this study was to estimate esophagectomy proﬁ-
ciency gain curves in terms of short- and long-term mortality in
esophageal cancer in a nationwide and comprehensive cohort
of patients.
PATIENTS AND METHODS
Design
The cohort used for this study has been described in detail else-
where.9,18 In brief, this Swedish nationwide cohort study included 98% of
all patients with esophageal cancer treated with a curative intent between
1987 and 2010, with follow-up until November 2014. From the Swedish
Cancer Registry, patients with a diagnosis of esophageal cancer (150.0,
150.8, or 150.9) were identiﬁed according to the seventh edition of the
International Classiﬁcation of Diseases (ICD7). This registry has 98%
nationwide coverage of esophageal cancer cases.19,20 Patients with esoph-
ageal cancer who underwent esophagectomy were identiﬁed from the
Swedish Patient Registry, which has an excellent positive identiﬁcation rate
(99.6%) for esophageal surgery.21 The Patient Registry also provided data
about patient medical comorbidities and reoperation.21 The comorbidities
were classiﬁed according to the well-validated Charlson comorbidity score
system.22 The Swedish Causes of Death Registry was used to provide
accurate data about the dates and causes of death. If the diagnosis of
esophageal cancer was listed as a cause of death, then mortality was deﬁned
as disease speciﬁc. The Swedish personal identity number, assigned to each
Swedish resident at birth or immigration, was used to link data between
registries and in the identiﬁcation of individual medical records. Medical
records that contained operation notes and histopathological reports of the
cohort members were retrieved from all Swedish hospitals where
esophageal cancer surgery was performed. Clinical data were collected
through a nationwide Swedish clinical network established in the mid-
1990s.23 Data about neoadjuvant therapy, names of the surgeons, tumor
pathologic stage, histologic subtype, and lymphadenectomy were obtained
from these individual patient records. The accuracy of histopathological
review has been previously described; two researchers independently
reviewed 100 records and demonstrated high accuracy with . 90%
concordance.24 Neoadjuvant therapy was predominantly used in more
recent years and, when used, was typically a combination of chemotherapy
and radiotherapy. Tumor stage was classiﬁed according to the TNM
classiﬁcation of the International Union Against Cancer (UICC).25 Only
open transthoracic esophageal resection was studied, and intrathoracic
anastomosis was most commonly used (95%). Minimally invasive
esophagectomy was performed in , 2% of cases in Sweden during the
study period, which did not permit additional analysis of the proﬁciency
gain curve. The regional ethical review board in Stockholm, Sweden,
approved the study.
Outcomes
The outcomes were 30-day, 90-day, 1-year, 3-year, and 5-year all-
cause and disease-speciﬁc mortality. To exclude the effect of earlier
mortality on the longer-term results, 90-day mortality was calculated from
30 to 90 days; 1-year mortality, from 90 days to 1-year; 3-year mortality,
from 1 year to 3 years; and 5-year mortality, from 3 years to 5 years. Lymph
node yield, reoperation, and resection margin status (R1/2) were examined
as explanatory performance-related variables to any changes in long-term
survival. R1 or R2 refer to microscopic or macroscopic presence of tumor
at the resection margin, respectively.
Statistical Analysis
Follow-up of patients ended at death, emigration, or the end of the
study period (November 2014), whichever occurred ﬁrst. According to the
unique anonymized surgeon codes within the database, the ﬁrst case in
each surgeon case series was assigned case one, and subsequent case
numbers were assigned according to ascending date order. Risk-adjusted
cumulative sum (RA-CUSUM) curves were created to deﬁne the proﬁ-
ciency gain curve for each mortality outcome from esophagectomy.26 Risk
prediction models for the binary outcomes were created by using logistic
regression models. Potential confounding factors included in the models
were age (continuous variable), sex (male or female), tumor histologic
subtype (adenocarcinoma or squamous cell carcinoma), pathologic stage
(stage I, II, III, or IV), use of neoadjuvant therapy (yes or no), and
individual preoperative comorbidities (yes or no). The risk prediction
models were used to calculate the predicted probability of each outcome in
each case (the expected survival or mortality; Appendix Table A1, online
only). The curves plot the cumulative difference between the observed and
expected mortality/survival (ie, CUSUM O [minus] E, on the y-axis)
according to the risk-adjustment model. This difference was calculated
using the CUSUM equation Si = Si21 + ( Si 2 SR); S0 = 0. Si is the
cumulative sum, Si is the sum of events at procedure number i, and SR is
the sum of expected events at procedure number i. RA-CUSUM curves
were also examined for lymph node harvest, positive resection margin, and
reoperation rates. On the basis of this equation, the curve increases if the
observed mortality/survival exceeds the expected mortality/survival and
vice versa.
It was expected that there would be an inverse relationship between
experience and mortality. Therefore the change-points were identiﬁed as
the maximal deﬂection of the curve from 0; the signiﬁcance of the change-
points was analyzed by comparing the relevant outcomes before and after.
Binomial outcomes were compared with the x2 test, and continuous
Table 1. Demographics of Patients Who Underwent Esophagectomy From
1987 to 2010
Variable No. (%) of Patients
Age, years
Median 66
Range 18-89
Male sex 1,361 (74.7)
Ischemic heart disease 150 (8.2)
Congestive cardiac failure 96 (5.3)
Peripheral vascular disease 64 (3.5)
Cerebrovascular disease 107 (5.9)
Chronic obstructive pulmonary disease 199 (10.9)
Diabetes 146 (8.0)
Liver disease 28 (1.5)
Renal disease 21 (1.2)
Charlson comorbidity score22
0-1 1,440 (79.1)
2-4 362 (19.9)
$ 5 19 (1)
Histologic tumor subtype
Adenocarcinoma 792 (43.5)
Squamous cell carcinoma 1,024 (56.2)
Pathologic tumor stage
0 177 (9.7)
I 245 (13.5)
II 662 (36.4)
III 582 (32.0)
IV 140 (7.7)
Missing 15 (0.8)
Neoadjuvant therapy 587 (32.2)
Missing 2 (0.1)
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Fig 1. Proﬁciency gain curves for (A) 30-day all-cause
mortality from esophagectomy for cancer with a signiﬁcant
change-point at 15 cases with a reduction from 7.9% to 3.1%
(P , .001); (B) 90-day all-cause mortality from esoph-
agectomy for cancer with a nonsigniﬁcant change-point at
22 cases with a reduction from 7.3% to 5.2% (P = .079);
(C) 30-day disease-speciﬁc mortality from esophagectomy
for cancer with a signiﬁcant change-point at 15 cases with a
reduction from7.3% to 2.5% (P, .001); and (D) 90-day disease-
speciﬁc mortality from esophagectomy for cancer with a sig-
niﬁcant change-point at 18 cases with a reduction from 7.1% to
4.3% (P = .043). Abbreviations: E, expected; O, observed.
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outcomes were compared with the Mann-Whitney U test. A threshold of
signiﬁcance was set at P , .05.
RESULTS
This study included 1,821 patients with esophageal cancer who
underwent esophagectomy, and these operations were performed
by a total of 139 surgeons. The median number of cases performed
by the surgeons was 16, and the interquartile range was six to 46
cases; the most experienced surgeon had performed 262 cases. The
median follow-up time was 491 days. The median age at surgery
was 66 years, a high proportion of patients (74.7%) were men, and
there was a relatively low rate of medical comorbidities (Charlson
score# 1 in 79.1% of patients). There was a greater proportion of
squamous cell cancers (56.2%) than adenocarcinomas (43.5%).
The majority of tumors were pathologic stage II (36.4%) or III
(32%), and 32.2% of patients received neoadjuvant therapy
(Table 1). Among this cohort, 1,272 patients (69.9%) had no
cancer in the resection margin (R0), whereas 281 patients (15.4%)
had cancer in the margin (R1/R2); 268 patients (14.7%) had
missing margin data.
Proficiency Gain Curve Analysis
Short-term mortality. The 30-day and 90-day measures were
short-term mortality data (Fig 1). The incidences of 30-day and
90-day all-cause mortality for the cohort were 5.3% and 6.4%,
respectively (Table 2). There were change-points in the proﬁciency
gain curves at 15 cases and 22 cases, respectively, at which point the
30-day all-cause mortality decreased from 7.9% to 3.1% (P, .001;
Fig 1A) and the 90-day all-cause mortality decreased from 7.3% to
5.2% (P = .079; Fig 1B).
The incidences of 30-day and 90-day disease-speciﬁc mor-
tality were 4.7% and 5.7%, respectively (Table 2). The RA-CUSUM
analysis for 30-day disease-speciﬁc mortality showed a change-
point at 15 cases, with a reduction from 7.3% to 2.5% (P, .001;
Fig 1C). The RA-CUSUM analysis for 90-day disease-speciﬁc
mortality showed a signiﬁcant change-point at 18 cases, and the
reduction in 90-day disease-speciﬁc mortality decreased from
7.1% to 4.3% (P = .017; Fig 1D).
Long-term mortality. The 1-, 3- and 5-year measures were
long-termmortality data (Figs 2 and 3). RA-CUSUManalysis of 1-year
all-cause mortality showed a signiﬁcant change-point at 53 cases,
with a reduction from 34.9% to 27.7% (P = .011; Fig 2A). A similar
signiﬁcant change-point was seen for 3-year all-cause mortality at
35 cases, with a reduction from 47.4% to 41.5% (P = .049; Fig 2B).
The RA-CUSUM analysis of 5-year all-cause mortality showed a
signiﬁcant change-point at 59 cases, with a reduction from 31.4% to
19.1% (P = .006; Fig 2C).
RA-CUSUM analysis of 1-year disease-speciﬁc mortality
showed a signiﬁcant change-point at 53 cases, with a reduction
from 31.8% to 24.7% (P = .01; Fig 3A). Similarly, a change-point
was seen for 3-year disease-speciﬁc mortality at 38 cases, with a
reduction from 39.4% to 32.8% (P = .034; Fig 3B). There was no
apparent proﬁciency gain curve seen with 5-year disease-speciﬁc
mortality (Table 2; Fig 3C).
Lymph Node Harvest, Resection Margin Status, and
Reoperation Incidence
There was a marked increase in lymph node harvest, although
it was not possible to deﬁne an exact change point because of the
smooth nature of the curve (Fig 4A). The RA-CUSUM analysis for
R1/2 resection margin status showed a signiﬁcant change-point at
17 cases, with a reduction from 20.9% to 15.2% (P = .004; Fig 4B).
RA-CUSUM analysis for reoperation showed a signiﬁcant change-
point at 55 cases, with a reduction from 12.6% to 5% (P , .001;
Fig 4C).
DISCUSSION
This study indicates that resection of esophageal cancer has a
proﬁciency gain curve with a measurable evolution in both short-
and long-term mortality. The change-points in proﬁciency gain
curve were earlier for short-term mortality (30- and 90-day
mortality), which ranged from 15 to 22 cases, than the later
Table 2. Outcomes Before and After Change-Points in Proﬁciency Gain Curves for All-Cause and Disease-Speciﬁc Mortality Results After Esophagectomy for Cancer
Mortality time point
Proﬁciency Gain
Curve Change-Point
(No. of cases)
% (No./ Total No.) With Outcome
Change-Point POverall Prior to Change-Point After Change-Point
All-cause
30-day 15 5.3 (94/1,761) 7.9 (65/825) 3.1 (29/936) , .001
90-day 22 6.4 (107/1,667) 7.3 (70/955) 5.2 (37/712) .079
1-year 53 33.3 (520/1,562) 34.9 (422/1,208) 27.7 (98/354) .011
3-year 35 45.4 (474/1,044) 47.4 (328/692) 41.5 (146/352) .049
5-year 59 28.6 (163/570) 31.4 (138/439) 19.1 (25/131) .006
Disease-speciﬁc
30-day 15 4.7 (83/1,761) 7.3 (60/825) 2.5 (23/936) ,.001
90-day 18 5.7 (96/1,678) 7.1 (60/850) 4.3 (36/828) .017
1-year 53 30.1 (477/1,583) 31.8 (388/1,222) 24.7 (89/361) .010
3-year 38 37.2 (412/1,107) 39.4 (294/747) 32.8 (118/360) .034
5-year No change-point NA NA NA NA
Abbreviation: NA, not available.
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change-points for long-term mortality (1-, 3- and 5-year mor-
tality) that ranged from 35 to 59 cases.
The relatively short length of the proﬁciency gain curve for
short-term mortality parallels published literature from single
institutions in open esophagectomy16 and a national study for
minimally invasive esophagectomy in England.17 There was a
5% reduction in 30-day mortality observed during the proﬁ-
ciency gain curve, which represents a non-negligible degree of
patient harm as surgeons gain operative experience. Impor-
tantly, the proﬁciency gain curve for long-term mortality was
longer. The initial focus of independent surgeon practice is
likely to be short-term outcome and, in particular, the 30-day
mortality. When early mortality has been reduced to an acceptable
level and when the surgeon gains the technical conﬁdence in
performing the procedure, surgeons then can reﬁne their tech-
niques and improve the quality of the resection, which will result
in better long-term survival.
There are several potential mechanisms that might con-
tribute to the ﬁndings about the learning curve in relation to
long-term survival. Although a higher lymph node yield with
more experience might be one such mechanism, a recent study
that was based on the same cohort as the present study showed
that lymph node harvest was not an independent predictor of
survival.18 Nevertheless, lymph node harvest in the current
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Fig 2. Proﬁciency gain curves for (A)
1-year all-cause mortality from esoph-
agectomy for cancer with a signiﬁcant
change-point at 53 cases with a reduction
from 34.9% to 27.7% (P =.011); (B) 3-year
all-cause mortality from esophagectomy
for cancer with a signiﬁcant change-point at
35 cases with a reduction from 47.4% to
41.5% (P = .049); and (C) 5-year all-cause
mortality from esophagectomy for cancer
with a signiﬁcant change-point at 59
caseswith a reduction from31.4% to19.1%
(P = .006). Abbreviations: E, expected; O,
observed.
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study might be a marker of improved oncologic surgical quality
with proﬁciency gain. The ﬁnding that cancer involvement in
the resection margin was overrepresented among surgeons in
the beginning of an esophagectomy career might well contrib-
ute to the higher longer-term mortality rates, because mar-
gin involvement is a prognostic factor.27 Finally, reductions in
reoperation incidence parallel ﬁndings from a study that was
based on the present database, which suggests that reoperation
affects long-term survival after esophagectomy.28
Gaining experience at the expense of patient safety or long-
term survival is unacceptable, and every effort must be made to
overcome the proﬁciency gain curve for both short- and long-
term mortality results. This study showed proﬁciency gain in an
established operation. Open esophagectomy is not a newly
A
–5
0
Procedure Number
CU
SU
M
 (O
-E
)
CU
SU
M
 (O
-E
)
CU
SU
M
 (O
-E
)
Procedure Number
Procedure Number
5
10
15
20
1 10 19 28 37 46 55 64 73 82 91 10
0
10
9
11
8
12
7
13
6
14
5
15
4
16
3
17
2
18
1
19
0
19
9
20
8
21
7
22
6
23
5
24
4
25
3
26
2
1-Year Disease-Specific Mortality
B
–10
–5
0
5
10
15
20
1 10 19 28 37 46 55 64 73 82 91 10
0
10
9
11
8
12
7
13
6
14
5
15
4
16
3
17
2
18
1
19
0
19
9
20
8
21
7
22
6
23
5
24
4
25
3
26
2
3-Year Disease-Specific Mortality
C
0
1
2
3
4
5
6
7
1 10 19 28 37 46 55 64 73 82 91 10
0
10
9
11
8
12
7
13
6
14
5
15
4
16
3
17
2
18
1
19
0
19
9
20
8
21
7
22
6
23
5
24
4
25
3
26
2
5-Year Disease-Specific Mortality
Fig 3. Proﬁciency gain curves for (A) 1-year
disease-speciﬁc mortality from esoph-
agectomy with a signiﬁcant change-point at
53 cases with a reduction from 31.8% to
24.7% (P = .01); (B) 3-year disease-speciﬁc
mortality fromesophagectomy for cancerwith
a signiﬁcant change-point at 38 cases with a
reduction from 39.4% to 32.8% (P = .034);
and (C) 5-year disease-speciﬁc mortality from
esophagectomy for cancer showing no sig-
niﬁcant pattern. Abbreviations: E, expected;
O, observed.
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introduced procedure; a proﬁciency gain curve has been tradi-
tionally observed during the dissemination of a technique, and
minimal-access surgery is the typical example.17 Nevertheless,
open esophagectomy is a technically demanding procedure in
which there is much to learn and optimize before proﬁciency can
be achieved. To shorten the proﬁciency gain curve and to minimize
avoidable harm to patients, we believe in two main strategies. The
ﬁrst is to base surgical training on structured programs that have a
competency-based assessment before embarking on independent
practice.29,30 Such a strategy can replace the current training system
on the basis of the number of procedures, the years of training, and
the subjective opinions of trainers. Second, this competency-based
training curriculum should be followed by a mentorship and
continual technical proﬁciency scheme to support specialists dur-
ing the initial phase of independent practice. A good example of
such a structured training programwas observed with the National
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Fig 4. Proﬁciency gain curves for lymph
node harvest from esophagectomy for cancer
showing (A) a continuous increase in lymph
node harvest with greater case load; (B) R1/2
resection margin from esophagectomy for
cancer showing a signiﬁcant change-point at
17 cases with a reduction from 20.9% to
15.2% (P = .004); and (C) reoperation from
esophagectomy for cancer showing a sig-
niﬁcant change-point at 55 cases with a
reduction from 12.6% to 5.0% (P , .001).
Abbreviations: E, expected; O, observed.
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Training Program for Laparoscopic Colorectal Surgery in England.
This program was a government initiative that facilitated the
training of surgeons in a structured, competency-based program
that shortened the proﬁciency gain curve and reduced patient
harm during the process of surgical learning.29-31
Methodological advantages of the current study include the
population-based design with complete and unbiased inclusion of
patients who had undergone esophagectomy for esophageal cancer
in Sweden since 1987. Moreover, the clinical data collection
combined with data available in the well-maintained registers
allowed us to perform this analysis and to adjust for several
potential confounding factors. Furthermore, the Swedish system
with nationwide and complete population registers made it pos-
sible to observe all patients, without loss to follow-up. Finally, the
large sample size improved the statistical power and counteracted
chance errors.
There are also limitations associated with retrospective obser-
vational studies such as this. Typically, national database studies are
limited by the quality of data entry; however, the data set used for
this study has high accuracy in the correct identiﬁcation of patients
who underwent esophagectomy for cancer and has a strong cor-
relation with pathology, including tumor stage. Moreover, the
medical records were retrieved and reviewed, which made it
possible to have detailed clinical data, including the surgeon name
as a variable required for this study. Additional unmeasured
surgical factors may have improved the oncologic quality and
long-term survival. Although the study period began in 1987 and,
therefore, represents one of the oldest existing national data sets for
esophagectomy, it is conceivable that a minority of surgeons may
have begun operating before 1987; thus, the early part of their
proﬁciency gain curve may not have been captured. The study
period is rather long; therefore, it is conceivable that improvements
in other areas over time, including clinical staging that led to better
patient selection for surgical intervention or improvements in
neoadjuvant therapy regimens and enhanced recovery protocols,
may have contributed to the improvement in short- and long-
term outcomes during the surgical proﬁciency gain. However, it is
important to note that case 1 was taken by surgeons at the start of
their practice and that the practices showed temporal variations
throughout the study period; despite the presumed improvements
seen in other areas, there was a quantiﬁable proﬁciency gain curve
in terms of short- and long-term survival. Finally, although risk
adjustment in CUSUM analysis did include pathologic stage,
histologic subtype, use of neoadjuvant therapy, and patient
demographics, including comorbidities, there may have been
additional unknown confounding factors that may have con-
tributed to the observed changes in survival.
In conclusion, to our knowledge, this is the ﬁrst study to
evaluate the change in long-termmortality at a national level as the
surgeon gains proﬁciency in performing open esophagectomy for
cancer, and shows that the length of the proﬁciency gain curve was
shorter for short-term than for long-term mortality. The adverse
impact of proﬁciency gains upon patient outcomes may be ne-
gated with competency-based training programs before surgeons
embark on independent practice that are followed by a mentoring
and a continual proﬁciency scheme during the initial practice as
specialists.
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Appendix
Table A1. Sample Logistic Regression Analysis Used For Risk-Adjusted
CUSUM Analysis of All-Cause 30-Day Mortality
Variable at step 1
Analysis Data
95% CI for ORP OR
Age at operation .000 .936 .911 to .961
Sex .310 .764 .454 to 1.285
Histology .001 2.249 1.387 to 3.646
Stage .738
I .220 2.104 .641 to 6.901
II .439 1.459 .560 to 3.799
III .687 1.172 .541 to 2.539
IV .510 1.304 .591 to 2.877
Neoadjuvant therapy .915 .973 .584 to 1.620
Ischemic heart disease .124 1.631 .874 to 3.041
Congestive cardiac failure .029 2.110 1.078 to 4.132
Peripheral vascular disease .091 1.989 .897 to 4.412
Cerebrovascular disease .426 1.331 .658 to 2.692
Chronic pulmonary disease .445 .760 .376 to 1.536
Diabetes .055 1.906 .986 to 3.683
Liver disease .693 .657 .082 to 5.286
Renal disease .038 4.009 1.081 to 14.871
Constant .028 41.580
Abbreviation: OR, odds ratio.
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